Abstract
Objectives Intermittent fasting boosts some mechanisms of host defense against infection while modulating the inflammatory response. Lower-frequency periodic fasting is associated with greater survival and lower risk of comorbidities that exacerbate COVID-19. This study evaluated the association of periodic fasting with COVID-19 severity and, secondarily, initial diagnosis of infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Design Prospective longitudinal observational cohort study.
Setting Single-center secondary care facility in Salt Lake City, Utah, USA with follow-up across a 24-hospital integrated healthcare system.
Participants Patients enrolled in the INSPIRE registry in 2013-2020 were studied if they had SARS-CoV-2 testing in March 2020-February 2021 and either tested positive (N=205) for the primary outcome evaluation or had a positive or negative test result for evaluation of the secondary outcome (n=1,524).
Interventions No treatment assignments were made; individuals provided information about their personal practice and history of engaging in routine periodic fasting across their lifespan.
Main outcome measures The association of periodic fasting with a composite of mortality or hospitalization as the primary outcome was evaluated by Cox regression through February 2021 and multivariable adjustments considered 36 covariables in INSPIRE patients diagnosed with COVID-19. Secondary analysis evaluated the association of fasting with testing positive for SARS-CoV-2 in INSPIRE patients evaluated for COVID-19 (n=1,524).
Results Subjects engaging in periodic fasting (n=73, 35.6%) did so for 40.4±20.6 years (max: 81.9 years) prior to COVID-19 diagnosis. The composite outcome occurred in 11.0% of periodic fasters and 28.8% of non-fasters (p=0.013), with HR=0.61 (95% CI=0.42, 0.90) favoring fasting. Multivariable analyses confirmed this association. Other predictors of hospitalization/mortality were age, Hispanic ethnicity, prior MI, prior TIA, and renal failure, with trends for race, smoking, hyperlipidemia, coronary disease, diabetes, heart failure, and history of anxiety, but not alcohol use. In secondary analysis, COVID-19 was diagnosed in 14.3% of fasters and 13.0% of non-fasters (p=0.51).
Conclusions Routine periodic fasting was associated with a lower risk of hospitalization or mortality in patients with COVID-19. Fasting may be a complementary therapy to vaccination that could provide immune support and hyperinflammation control during and beyond the pandemic.
Trial registration clinicaltrials.gov, NCT02450006 (the INSPIRE registry)
What is already known on this topic
During a period of energy restriction, fasting controls inflammation by dampening the cytokine cascade and it switches the metabolic source of energy from glucose to fats, including by increasing circulating free fatty acids such as linoleic acid.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domains bind linoleic acid in pockets that, when bound, reduce spike protein affinity for the angiotensin-converting enzyme 2.
Repeated fasting boosts basal levels of some parameters related to inflammation control and host defense against infections, including galectin-3, and it ameliorates insulin resistance and cardiovascular risks such that periodic fasting is associated with greater survival and lower risk of heart failure, coronary artery disease, and type 2 diabetes.
What this study adds
This study evaluated the association of periodic fasting with severity of coronavirus disease 2019 (COVID-19) and with initial infection with SARS-CoV-2 in a population where a substantial proportion of people routinely engage in periodic dry or water-only fasting, primarily for religious purposes.
This observational epidemiologic study found that routine low-frequency periodic fasting for an average of >40 years was associated with a lower risk of a composite of hospitalization or mortality after COVID-19 diagnosis, suggesting that fasting deserves further investigation as a complementary approach along with vaccines for reducing COVID-19 severity.
The study also found no association of periodic fasting with the onset of SARS-CoV-2 infection.
Trial registration The Intermountain INSPIRE registry (clinicaltrials.gov, NCT02450006)
Transparency BDH affirms that the manuscript is an honest, accurate, and transparent account of the study being reported and that no important aspects of the study have been omitted.
Copyright The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest / and declare: funding from the Intermountain Research and Medical Foundation through the philanthropy of the Dell Loy Hansen Heart Foundation for the submitted work; BDH has also received other research grants from the Intermountain Research and Medical Foundation for other fasting-related studies, but the authors have no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; BDH is a member of the scientific advisory boards of Opsis Health and Lab Me Analytics outside of the submitted work, BDH received a grant from AstraZeneca for pre-pandemic clinical risk prediction in percutaneous coronary intervention outside the submitted work, and BDH, HTM, and JLA are inventors of clinical decision tools that are licensed to CareCentra and Alluceo.
Funding Statement
This research was funded by a grant from the Intermountain Research and Medical Foundation through the philanthropy of the Dell Loy Hansen Heart Foundation (PI: BDH). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Intermountain Healthcare institutional review board approved the INSPIRE registry as a prospective databasing and biobanking resource (IRB #1024811). Subjects provided consent to participate and the INSPIRE registry collected clinical data, survey information, biological samples, and longitudinal outcomes of patients seen at Intermountain Medical Center in Salt Lake City, UT, USA. INSPIRE is detailed at clinicaltrials.gov (NCT02450006). This study of periodic fasting and COVID-19 outcomes evaluated INSPIRE data and was approved by the Intermountain Healthcare institutional review board (IRB #1051223).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this article cannot be shared publicly due to United States privacy laws. The data will be shared contractually on reasonable request to the corresponding author.
